Biotech Bay
Filter News
Found 69,451 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
BioSpace Movers & Shakers, June 18
6/18/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/18/2021
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share
-
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
6/18/2021
Aditx Therapeutics, Inc. announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
-
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
6/18/2021
Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company’s President, Product Development and Medical Affairs and Chief Medical Officer, has begun a medical leave of absence.
-
Lyell Immunopharma Announces Pricing of Initial Public Offering
6/17/2021
Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced the pricing of its initial public offering of 25,000,000 shares of its common stock at a public offering price of $17.00 per share
-
Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
6/17/2021
Innovent Biologics, Inc. ("Innovent", HKEX: 01801), announced that the first patient has been dosed in a Phase II basket trial of taletrectinib for solid tumors containing NTRK fusion (NCT04617054).
-
Atomwise Adds Pharma Luminaries to Board of Directors and Scientific Advisory Board
6/17/2021
Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB).
-
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/17/2021
Gritstone bio, Inc. today announced that the Compensation Committee of the company’s Board of Directors has granted five employees nonqualified stock options.
-
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications
6/17/2021
Surrozen Inc. announced today that data from preclinical studies were presented in four oral Abstract Flash Talk presentations during The Liver Biology Conference.
-
AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials
6/17/2021
AcelRx Pharmaceuticals, Inc. , today announced it has reached agreement with the Food and Drug Administration (FDA) with regards to finalizing corrective actions in a warning letter.
-
Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology
6/17/2021
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial in the Journal of Clinical Oncology in a paper entitled, “Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.”
-
CareDx CEO Reg Seeto to Present at AAKP 4th Annual Policy SummitReg Seeto will present on technology that enables transplant patient care at the AAKP 2021 Summit
6/17/2021
CareDx, Inc. announced that Reg Seeto, President and CEO of CareDx, will present "Improving Access to Transplant Care:Telehealth & Technology to Enable Patients Along the Transplant Journey," at the American Association of Kidney Patients 4th Annual Policy Summit, which will be held virtually on June 17, 2021.
-
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
6/17/2021
FibroGen, Inc. and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs.
-
Medable Hires Sanskriti Thakur as Chief Growth Officer to Lead Market Expansion
6/17/2021
Medable Inc. , the leading cloud platform for patient-centered drug development, today announced the hiring of Sanskriti Thakur as chief growth officer.
-
Cala Health and University of California, San Francisco Announce Partnership to Develop Next-Generation, Smart Neuromodulation Therapies
6/17/2021
Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, announced a partnership with University of California, San Francisco to develop non-invasive, individualized, peripheral nerve stimulation therapies that leverage Cala Health’s neuromodulation and data science platform technology.
-
Codexis Raises 2021 Guidance Following Receipt of Significant New Order for a Proprietary Enzyme Product
6/17/2021
Codexis, Inc., a leading enzyme engineering company enabling the promise of synthetic biology, is raising its guidance for 2021, following the receipt of a binding purchase order for up to $13.9 million of a proprietary high performance enzyme product from an undisclosed global pharmaceutical company.
-
Sparta Science and USC's Center for Body Computing Collaborate on New Research Testing the Effectiveness of Tools Used for Assessing Injury-Risk in U.S. Servicemembers
6/17/2021
Sparta Science has partnered with the University of Southern California's Center for Body Computing to conduct a series of iterative research studies aimed at understanding how to best utilize force plates and machine learning algorithms to predict risk for and mitigate musculoskeletal injuries within U.S. military servicemembers.
-
This week, the German drug company announced that it is closing the doors to its 'innovation hub' in Mission Bay.